Cosentyx is the only IL-17A inhibitor approved for this population, and the first differentiated mechanism in nearly a decade1-3 HS often emerges around…
New facility will enable end‑to‑end discovery across key disease areas and technology platforms, joining existing global research sites including Cambridge,…